Models for predicting hepatitis B e antigen seroconversion in response to interferon-&alpha; in chronic hepatitis B patients

doi:10.3748/wjg.v21.i18.5668

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11182)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

393

WORD

191

HTML

3612

Figures (1-2)

322

Tables (1-4)

295

Sum=4813

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

555

Download

1662

Sum=2217

Publishing Process of This Article

Item

Count

Browse

1206

Download

2946

Sum=4152

May 14, 2015 (publication date) through Apr 3, 2025

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastroenterol. May 14, 2015; 21(18): 5668-5676
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5668

Table 1 Individual factors of patients with diverse responses at 52 wk after interferon-α therapy n (%)

Characteristic	Total (n = 147)	RS (n = 47)	NRS (n = 100)
Sex
Male	106 (72.1)	33 (70.2)	73 (73.0)
Female	41 (27.9)	14 (29.8)	27 (27.0)
Age (yr)	25.02 ± 056	26.40 ± 1.19	24.37 ± 0.59
ALT (U/L)	214.25 ± 17.38	226.23 ± 19.19	208.62 ± 23.94
HBV DNA
(log₁₀ copies/mL)	7.16 ± 0.07	6.93 ± 0.14	7.27 ± 0.09
HBsAg
(log₁₀ IU/mL)	4.11 ± 0.07	3.93 ± 0.14	4.20 ± 0.07
HBeAg
(log₁₀ S/CO)	2.55 ± 0.07	2.30 ± 0.13^a	2.67 ± 0.07^a
Anti-HBc (S/CO)	11.13 ± 0.15	11.54 ± 0.27	10.94 ± 0.17
Genotype
B	85 (57.8)	26 (55.3)	59 (59.0)
C	55 (37.4)	21 (44.7)	34 (34.0)
Other	7 (4.8)	0 (0.0)	7 (7.0)

Data are presented as frequency counts (percentage of total) or mean ± SD.

^aP < 0.05, NRS vs RS. RS: HBeAg seroconversion; NRS: No HBeAg seroconversion; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBc: Antibody to hepatitis B core antigen.

Table 2 Factors at baseline influencing hepatitis B e antigen seroconversion in treated patients evaluated using univariate and multivariate analyses n (%)

Parameter	RS	Univariate analysis	P value	Multivariate analysis	P value
Parameter	RS	OR (95%CI)	P value	OR (95%CI)	P value
Female gender	14 (34.1)	1.15 (0.53-2.47)	0.725
Age > 24 yr	26 (40.0)	1.94 (0.96-3.91)	0.065
ALT > 4 × ULN	33 (44.6)	3.39 (1.62-7.12)	0.001	2.44 (1.10-5.42)	0.028
HBV DNA ≤ 7
log₁₀ copies/mL	22 (39.3)	1.71 (0.84-3.46)	0.138
HBsAg ≤ 15000 IU/mL	27 (40.3)	2.03 (1.00-4.09)	0.049
HBeAg ≤ 500 S/CO	26 (47.3)	3.03 (1.48-6.22)	0.003	2.12 (0.97-4.64)	0.060
anti-HBc > 11.4 S/CO	33 (45.8)	3.69 (1.75-7.75)	0.001	3.02 (1.39-6.57)	0.005
Genotype B	26 (30.6)	0.91 (0.50-1.65)	0.749

ALT: Alanine aminotransferase; ULN: Upper limit of normal; HBV: Hepatitis B virus; HBsAg: hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBc: Antibody to hepatitis B core antigen; RS: Patients with HBeAg seroconversion.

Table 3 Factors at 12 wk influencing hepatitis B e antigen seroconversion in treated patients evaluated using univariate and multivariate analyses n (%)

Parameter	RS	Univariate analysis	P value	Multivariate analysis	P value
Parameter	RS	OR (95%CI)	P value	OR (95%CI)	P value
ALT > 7 × ULN	8 (61.5)	3.90 (1.20-12.66)	0.024
HBV DNA ≤ 5 log₁₀ copies/mL	31 (53.4)	5.24 (2.48-11.06)	< 0.001
HBsAg ≤ 10000 IU/mL	41 (48.2)	8.70 (3.39-22.34)	< 0.001
HBeAg ≤ 250 S/CO	44 (55.7)	27.24 (7.89-94.09)	< 0.001	10.90 (2.63-45.27)	0.001
anti-HBc > 11.8 S/CO	23 (47.9)	2.88 (1.39-5.96)	0.005	3.72 (1.41-9.84)	0.008
Decline ALT > 3 × ULN	20 (40.0)	1.73 (0.84-3.55)	0.136
Decline HBV DNA > 1.5 log₁₀ copies/mL	34 (48.6)	4.65 (2.18-9.93)	< 0.001
Decline HBsAg > 0.5 log₁₀ IU/mL	29 (55.8)	5.39 (2.55-11.42)	< 0.001
Decline HBeAg > 1 log₁₀ S/CO	34 (66.7)	12.77 (5.60-29.14)	< 0.001	4.53 (1.59-12.91)	0.005
Decline anti-HBc > 0.5 S/CO	13 (40.6)	1.64 (0.53-5.07)	0.393

ALT: Alanine aminotransferase; ULN: Upper limit of normal; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; anti-HBc: Antibody to hepatitis B core antigen; RS: Patients with HBeAg seroconversion.

Table 4 Factors at 24 wk influencing hepatitis B e antigen seroconversion in treated patients evaluated using univariate and multivariate analyses n (%)

Parameter	RS	Univariate analysis	P value	Multivariate analysis	P value
Parameter	RS	OR (95%CI)	P value	OR (95%CI)	P value
ALT ≤ 1 × ULN	25 (45.5)	2.65 (1.30-5.42)	0.008
HBV DNA ≤ 4 log10 copies/mL	32 (50.8)	4.48 (2.25-10.01)	< 0.001
HBsAg ≤ 2000 IU/mL	33 (52.4)	5.50 (2.58-11.73)	< 0.001
HBeAg ≤ 5 S/CO	41 (65.1)	24.23 (9.11-64.47)	< 0.001	16.82 (5.07-55.79)	< 0.001
anti-HBc > 11.4 S/CO	30 (44.8)	3.01 (1.46-6.18)	0.003	3.01 (1.20-7.56)	0.019
Decline ALT > 2 × ULN	35 (42.2)	3.16 (1.47-6.78)	0.003
Decline HBV DNA > 2 log₁₀ copies/mL	36 (46.8)	4.71 (2.15-10.32)	< 0.001
Decline HBsAg > 1 log₁₀ IU/mL	26 (49.1)	3.35 (1.62-6.91)	0.001
Decline HBeAg > 2 log₁₀ S/CO	30 (66.7)	10.00 (4.45-22.47)	< 0.001	1.85 (0.62-5.49)	0.269
Decline anti-HBc > 0.5 S/CO	19 (47.5)	2.55 (1.20-5.43)	0.015

Citation: Wang CT, Zhang YF, Sun BH, Dai Y, Zhu HL, Xu YH, Lu MJ, Yang DL, Li X, Zhang ZH. Models for predicting hepatitis B e antigen seroconversion in response to interferon-α in chronic hepatitis B patients. World J Gastroenterol 2015; 21(18): 5668-5676
URL: https://www.wjgnet.com/1007-9327/full/v21/i18/5668.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i18.5668